Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oxypertine
- Development stage
- Discontinued
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Oxypertine is a small molecule antipsychotic drug of the tryptamine and phenylpiperazine classes, originally introduced in the 1960s for the treatment of schizophrenia and other psychoses. It was also evaluated for severe anxiety and mania. Oxypertine acts primarily as an antagonist at serotonin 5‑HT₂ and dopamine D₂ receptors, with high affinity for both targets. Its mechanism includes depletion of catecholamines (dopamine and norepinephrine) in the brain, while sparing serotonin to a greater extent than reserpine or tetrabenazine. The drug’s neuroleptic efficacy is attributed to these actions on monoaminergic neurotransmission. Oxypertine is structurally related to other "pertines" such as alpertine, milipertine, and solypertine[1][4][6].
- Brand names
- EquipertineForitIntegrinLanturilLotawinOpertilOxypertine
- Other names
- oxypertine
02
Targets
DRD2 (Dopamine D2 Receptor)HTR2A (Serotonin receptor 5-HT2A)
Beyond the preview
Go deeper on oxypertine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oxypertine.